Salts and esters of apx3330 and therapeutic uses thereof
AssigneeOpus Genetics, Inc.
InventorsDaniela Carmen ONICIU, Corina-Mihaela MANTA, Anthony CARESTIA, Jon HOUSLEY
Life of this patent
Estimating the term…
Loading patent…
AssigneeOpus Genetics, Inc.
InventorsDaniela Carmen ONICIU, Corina-Mihaela MANTA, Anthony CARESTIA, Jon HOUSLEY
Estimating the term…
This invention relates to Compound 1 (APX3330) salts and esters. The invention also provides compositions comprising a Compound 1 salt or ester. The invention also provides compounds of formula (I) and formula (II) and pharmaceutically acceptable salts thereof. The invention further provides compositions comprising a compound of formula (I) or formula (II), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or vehicle. The invention also provides methods for treating or preventing a disease, such as cancer, a liver disorder, an ocular disorder, a cardiovascular disorder, fibrosis, or an inflammatory disorder, comprising administering to a subject in need thereof an effective amount of a Compound 1 salt or ester; or compound of formula (I) or formula (II), or pharmaceutically acceptable salt thereof.
-7. (canceled)
Compound 1 calcium salt that exhibits an X-ray powder diffraction (XRPD) pattern comprising a peak at 8.0±0.2 degrees 2-theta and a peak at 10.1±0.2 degrees 2-theta.
Compound 1 calcium salt that exhibits an X-ray powder diffraction (XRPD) pattern comprising a peak at 5.1±0.2 degrees 2-theta, a peak at 8.0±0.2 degrees 2-theta, a peak at 10.1±0.2 degrees 2-theta, a peak at 13.3±0.2 degrees 2-theta, a peak at 14.6±0.2 degrees 2-theta, and a peak at 18.5±0.2 degrees 2-theta.
-12. (canceled)
Compound 1 calcium salt that exhibits an XRPD pattern that is substantially the same as that depicted in FIG. 2A.
-27. (canceled)
-35. (canceled)
-100. (canceled)
Dependencies are inferred from the claim text.